Role of Novel RADA16 Hydrogel in Endoscopic Skull Base Surgery

Last updated: June 28, 2024
Sponsor: Indiana University
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

PuraGel (RADA16) Hydrogel

Non-Absorbable Packing (Silastic Splint)

Clinical Study ID

NCT05898074
14045
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The purpose of this study is to specifically evaluate the effectiveness of PuraGel, a RADA16 polypeptide hydrogel, in expediting post-operative healing and re-mucosalization of the nasoseptal flap harvest site during endoscopic skull base surgery and the impact on patient and sinonasal morbidity.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patient is 18 years of age or older

  • Patient is undergoing endoscopic endonasal approach for the management of a skullbase tumor or cerebrospinal fluid leak. Nasoseptal Flap must be harvested.

  • Patient is undergoing surgery via bi-nostril approach requiring bilateral surgicaldissection of the nasal cavity in approach to the skull base

Exclusion

Exclusion Criteria:

  • Patient has evidence of radiographic baseline sinus disease consistent with acute orchronic rhinosinusitis (including nasal polyposis, prior septal perforation) onpre-operative CT sinus

  • Patient has had prior sinonasal surgery or has undergone sinonasal radiationtreatment

  • Patient has a known coagulation disorder or immune deficiency.

Study Design

Total Participants: 30
Treatment Group(s): 2
Primary Treatment: PuraGel (RADA16) Hydrogel
Phase:
Study Start date:
October 09, 2023
Estimated Completion Date:
October 09, 2025

Study Description

Briefly, multiple agents exist and have been long-studied in endoscopic sinus and septal surgery, which include non-absorbable agents and biodegradable, absorbable synthetic agents including extracellular matrix (ECM) based compounds and synthetic biopolymers. The goal of these agents has often been to reduce sinonasal crusting, postoperative bleeding, and synechia formation. With advancements in postoperative adjuncts, many options now exist for postoperative sinonasal packing including medicated products such as steroid-impregnated stents and chitosan-based absorbable packs.

Lastly, with respect to intra-operative adjuncts designed to foster healing in the postoperative period, PuraGel, a RADA16 polypeptide hydrogel, was identified as an ECM-based solution, which aids in wound healing, adhesion prevention, and hemostasis at the completion of the case. In hydrogel format, this agent forms a synthetic matrix that serves as a scaffold for mucosal healing while serving as a mechanical barrier on tissue surfaces, thereby limiting scarring. To date, there have been no studies evaluating the role of this gel-based compound in the postoperative period in endoscopic skull base surgery.

Thus, amongst all of these agents that have been previously studied to some degree in patients undergoing endoscopic sinus surgery, there has been limited study on their role in endoscopic skull base surgery and utility in reducing sinonasal morbidity in the postoperative setting. Therefore, our goal was to investigate and compare the impact of varying sinonasal agents in the nasal cavity following endoscopic skull base surgery. We hypothesize that the absorbable, ECM-based gel compound (PuraGel) demonstrates an improvement on postoperative healing rate and sinonasal crusting with reduced patient morbidity and improved patient comfort when compared to non-absorbable agents.

Connect with a study center

  • Indiana University

    Indianapolis, Indiana 46202
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.